The World Health Organization concludes that ETEC remains a priority pathogen and is encouraged by our preliminary phase 2B results from Benin
PDVAC will continue to advocate for and support the development of a ETEC vaccine and our vaccine candidate ETVAX® was described as the most advanced ETEC candidate with encouraging phase 2b study data.